Removal of Endobronchial Malignant Mass by Cryotherapy Improved Performance Status to Receive Chemotherapy

Abstract EN

Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment.

Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated.

Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method.

There were 59 patients (42 males), with median age of 64 years (range, 51–76, and median performance status of 2 (interquartile range [IQR], 2-3).

Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40).

The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10–0.69).

The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10–0.81).

Cryotherapy is a feasible treatment for MEM.

With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.